Humacyte (NASDAQ:HUMA) Trading Down 3% – Time to Sell?

Humacyte, Inc. (NASDAQ:HUMA) fell 3% on Tuesday . The stock traded as low as $4.43 and last traded at $4.51. 3,525,988 shares traded hands during trading, an increase of 27% from the average session volume of 2,777,449 shares. The stock had previously closed at $4.65.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on HUMA shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $13.00 target price on shares of Humacyte in a report on Friday, September 20th. TD Cowen reiterated a “buy” rating and issued a $10.00 price objective on shares of Humacyte in a report on Friday, October 18th. BTIG Research reissued a “buy” rating and set a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. Benchmark raised their price target on shares of Humacyte from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday. Finally, Piper Sandler set a $6.00 price objective on shares of Humacyte and gave the stock a “neutral” rating in a research note on Friday, October 18th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $13.71.

Humacyte Price Performance

The business’s fifty day simple moving average is $4.81 and its 200 day simple moving average is $5.81. The firm has a market capitalization of $567.62 million, a price-to-earnings ratio of -3.37 and a beta of 1.38. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 1.10.

Insider Buying and Selling at Humacyte

In other Humacyte news, Director Brady W. Dougan sold 427,459 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the transaction, the director now directly owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. This trade represents a 17.67 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Laura E. Niklason sold 811,172 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $4.44, for a total transaction of $3,601,603.68. Following the completion of the sale, the chief executive officer now owns 2,419,712 shares of the company’s stock, valued at approximately $10,743,521.28. This represents a 25.11 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,500,000 shares of company stock worth $6,606,799. 11.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Humacyte

A number of hedge funds have recently made changes to their positions in HUMA. State Street Corp raised its stake in Humacyte by 66.1% in the 3rd quarter. State Street Corp now owns 4,764,155 shares of the company’s stock valued at $25,917,000 after acquiring an additional 1,895,529 shares during the period. Geode Capital Management LLC lifted its stake in shares of Humacyte by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,040,218 shares of the company’s stock valued at $11,101,000 after buying an additional 179,120 shares in the last quarter. Millennium Management LLC boosted its holdings in Humacyte by 504.3% in the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock worth $7,677,000 after buying an additional 1,334,641 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Humacyte by 10.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 721,318 shares of the company’s stock valued at $3,924,000 after acquiring an additional 66,946 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in shares of Humacyte by 693.0% in the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock worth $2,881,000 after acquiring an additional 524,600 shares during the period. 44.71% of the stock is currently owned by institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.